XNCR Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

10.860

Open

10.730

VWAP

10.63

Vol

376.43K

Mkt Cap

820.01M

Low

10.440

Amount

4.00M

EV/EBITDA(TTM)

--

Total Shares

74.14M

EV

483.59M

EV/OCF(TTM)

--

P/S(TTM)

8.48

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Show More

Events Timeline

(ET)

2026-05-12

16:20:00

Major Averages Finish Mixed as Semiconductor Stocks Pull Back

2026-05-12

10:50:00

Trump Plans to Reduce Beef Import Tariffs

2026-05-11 (ET)

2026-05-11

12:30:00

Trump Approves Firing of FDA Commissioner Makary

2026-05-11

10:20:00

Trump Plans to Fire FDA Commissioner, Biotech Stocks Affected

2026-05-08 (ET)

2026-05-08

16:30:00

Dow Jones Slightly Up, Nasdaq Surges After Jobs Report

2026-05-08

13:40:00

Trump Signs Plan to Fire FDA Commissioner Makary

2026-05-06 (ET)

2026-05-06

16:10:00

Xencor Plans to Present XmAb819 Data in Second Half of 2026

2026-05-04 (ET)

2026-05-04

08:30:00

Xencor Reports Final Results from Phase 1 Study of XmAb942

News

Newsfilter

05-18Newsfilter

MindWalk Reports Significant Progress in Drug Development

NASDAQ.COM

03-24NASDAQ.COM

US Stocks Decline Amid Ongoing Iran Conflict

NASDAQ.COM

03-24NASDAQ.COM

US Stocks Decline Amid Ongoing Iran Conflict

NASDAQ.COM

03-24NASDAQ.COM

US Stocks Decline Amid Ongoing Iran Conflict

seekingalpha

03-05seekingalpha

Xencor Lowers Outlook After Royalty Dispute

Benzinga

Xencor Lowers Revenue Outlook for Ultomiris Royalties

5 Analyst Rating

Wall Street analysts forecast XNCR stock price to rise

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

20.00

Averages

26.25

High

30.00

Current: 0.000

Low

20.00

Averages

26.25

High

30.00

JPMorgan

Neutral

maintain

$13 -> $14

AI Analysis

2026-05-11

Reason

JPMorgan

Price Target

$13 -> $14

AI Analysis

2026-05-11

maintain

Neutral

Reason

JPMorgan raised the firm's price target on Xencor to $14 from $13 and keeps a Neutral rating on the shares.

JPMorgan

Overweight -> Neutral

downgrade

$18 -> $13

2026-03-24

Reason

JPMorgan

Price Target

$18 -> $13

2026-03-24

downgrade

Overweight -> Neutral

Reason

JPMorgan downgraded Xencor to Neutral from Overweight with a price target of $13, down from $18. The firm views the company's 2026 as an "execution year." Xencor's pipeline will need time to develop, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for XNCR

Unlock Now

Valuation Metrics

The current forward P/E ratio for Xencor Inc (XNCR.O) is 68.03, compared to its 5-year average forward P/E of -3.61. For a more detailed relative valuation and DCF analysis to assess Xencor Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-3.61

Current PE

68.03

Overvalued PE

17.68

Undervalued PE

-24.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-3.97

Current EV/EBITDA

-0.52

Overvalued EV/EBITDA

12.39

Undervalued EV/EBITDA

-20.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

13.39

Current PS

7.42

Overvalued PS

19.15

Undervalued PS

7.63

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

of all the listed stocks pick one please

Intellectia · 111 candidates

Price: $5.00 - $75.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEWeek Price Change Pct: >= $5.00One Day Rise Prob: >= 65Monthly Average Dollar Volume: >= 1,500,000

Ticker

Name

Market Cap$

Rayonier Advanced Materials Inc

685.47M

Adeia Inc

2.26B

Imax Corp

1.96B

Disc Medicine Inc

2.53B

Farmland Partners Inc

564.25M

Tanger Inc

4.31B

stock of the day for swing trade

Intellectia · 517 candidates

Price: $10.00 - $150.00Rsi Category: moderateRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20One Week Predict Return: >= 0.0%Monthly Average Dollar Volume: >= 1,500,000

Ticker

Name

Market Cap$

Celldex Therapeutics Inc

2.05B

Xencor Inc

855.50M

Montrose Environmental Group Inc

826.19M

Thomson Reuters Corp

44.22B

Phathom Pharmaceuticals Inc

961.13M

CAVA Group Inc

9.94B

Whales Holding XNCR

EcoR1 Capital, LLC

TCG Crossover Management, LLC

BVF Partners L.P.

RTW Investments, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Xencor Inc (XNCR) stock price today?

The current price of XNCR is 10.59 USD — it has decreased -4.25

What is Xencor Inc (XNCR)'s business?

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

What is the price predicton of XNCR Stock?

Wall Street analysts forecast XNCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XNCR is26.25 USD with a low forecast of 20.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Xencor Inc (XNCR)'s revenue for the last quarter?

Xencor Inc revenue for the last quarter amounts to 4.52M USD, decreased -86.20

What is Xencor Inc (XNCR)'s earnings per share (EPS) for the last quarter?

Xencor Inc. EPS for the last quarter amounts to -1.71 USD, increased 159.09

How many employees does Xencor Inc (XNCR). have?

Xencor Inc (XNCR) has 260 emplpoyees as of May 20 2026.

What is Xencor Inc (XNCR) market cap?

Today XNCR has the market capitalization of 820.01M USD.